Healthcare / Drug Manufacturers - Specialty & GenericBSE
$510.25
+10.95 (+2.19%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-478.9M · quality 61.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
56/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$99.8B
P/E
41.0x
↑EV/EBITDA
19.8x
↑ROE
9.4%
↑Gross Margin
70.1%
↑Debt/Equity
0.25
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+13.8%
FCF CAGR
—
FCF margin
-1.8%
FCF / Net income
-0.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $15.39B · net income $2.43B · FCF $-284.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $15.39B | $15.39B | $12.86B | $11.52B | $10.43B |
| Net Income | $2.43B | $2.43B | $783.0M | $318.7M | $-325.3M |
| EBITDA | $5.35B | $5.35B | $3.48B | $2.46B | $1.13B |
| EPS | — | — | 4.02 | 1.83 | -1.88 |
| Gross Margin | 70.1% | 70.1% | 68.1% | 64.5% | 60.1% |
| Operating Margin | 24.4% | 24.4% | 19.0% | 11.6% | -0.4% |
| Net Margin | 15.8% | 15.8% | 6.1% | 2.8% | -3.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.25 | 0.25 | 0.25 | 0.52 | 0.45 |
| Current Ratio | 1.31 | 1.31 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-284.5M | $-284.5M | $-1.11B | $-478.9M | $-467.4M |
| Returns | |||||
| ROE | 9.4% | 9.4% | 3.3% | 1.8% | -1.8% |
| Valuation | |||||
| P/E | 41.05 | 41.05 | 78.33 | 134.80 | — |
| EV/EBITDA | 19.82 | 19.82 | 19.22 | 21.15 | 25.04 |
| P/B | 3.85 | 3.85 | 2.60 | 2.38 | 1.16 |
| Growth & Yield | |||||
| Revenue Growth | 19.6% | 19.6% | 11.7% | 10.4% | — |
| EPS Growth | — | — | 119.1% | 197.9% | — |
| Dividend Yield | 0.1% | 0.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.8%
Start / end P/E
n/dx → n/dx
EPS bridge
4.02 → n/d
Residual
+14.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.